A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.

Details

Language :

English

ISSN :

0008543X

Volume :

116

Issue :

6

Database :

Academic Search Index

Journal :

Cancer (0008543X)

Publication Type :

Academic Journal

Accession number :

105158885

Full Text :

https://doi.org/10.1002/cncr.24821